SGEN - Seagen: Long-Term Pharma Stock To Own Based On Sales Growth And Oncology Portfolio
- Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%.
- TIVDAK was approved in September of 2021 for recurrent or metastatic cervical cancer, potential to expand use of the drug for squamous cell carcinoma of the head and neck.
- PADCEV is being expanded for use in 1st line metastatic urothelial carcinoma and muscle invasive bladder cancer.
- There are 13 clinical stage programs in the pipeline for hematologic malignancies and solid tumors.
For further details see:
Seagen: Long-Term Pharma Stock To Own Based On Sales Growth And Oncology Portfolio